Wegovy is manufactured by Novo Nordisk, a global healthcare company known for its leadership in diabetes care.

Wegovy is a GLP-1 (Glucagon-Like Peptide-1) receptor agonist. This class of drugs mimics the action of the GLP-1 hormone, which plays an important role in blood sugar regulation and appetite control.

The active ingredient in Wegovy is semaglutide, a compound designed to activate GLP-1 receptors in the body.

Wegovy is available in several strengths. Treatment for obesity typically starts at a dose of 0.25mg of semaglutide once a week for the first month, which can be gradually increased based on the patient’s response and tolerance. The highest strength dose is 2.4mg per week.

Wegovy is taken once a week in the form of an injection. The specific dosage and schedule will be determined based on individual needs and medical history. A typical treatment starts as follows:

– Weeks 1-4: 0.25mg (once a week)

– Weeks 5-8: 0.5mg (once a week)

– Weeks 9-12: 1.0mg (once a week)

– Weeks 13-16: 1.7mg (once a week)

– Weeks 17 and beyond: 2.4mg (once a week)

Yes. In the UK, Wegovy is approved by the MHRA as a weight loss treatment, and a weight management medication in conjunction with diet and exercise.

Wegovy mimics the action of the GLP-1 hormone, by stimulating insulin production, which helps regulate blood sugar levels. Additionally, it slows down stomach emptying, which makes you feel fuller for a longer period and reduces overall food intake. These combined effects aid in managing blood sugar levels and improving metabolic health.

Wegovy’s active ingredient is semaglutide. Here’s a more detailed look at its mechanism of action:

• semaglutide binds to GLP-1 receptors in the pancreas, enhancing insulin secretion in response to meals. This helps lower blood sugar levels effectively.
• By slowing gastric emptying, semaglutide prolongs the feeling of fullness after eating, which reduces overall calorie intake.
• semaglutide also inhibits glucagon secretion, which prevents the liver from producing too much glucose.

For more information see the manufacturer’s Patient Information Leaflet for Wegovy.

Clinical trials have shown that Wegovy is effective in promoting significant weight loss. In a series of studies, more than half of participants who took Wegovy for 2 years sustained an average weight loss of 15% (see source). By comparison one alternative weight loss injection – Mounjaro – has shown to enable up to 26% weight loss over 84 weeks.

Anecdotally, many people who have taken Wegovy also report positive outcomes beyond clinical measures. As well as substantial weight loss, patients frequently mention that their general quality of life has improved since taking Wegovy. For instance, some users have shared that they feel more energetic, have better mobility, and experience less joint pain. Others have highlighted the psychological benefits, such as increased confidence and reduced anxiety about their health.

Direct health benefits

• Significant weight loss can lower blood sugar levels and improve insulin sensitivity, reducing the risk of developing type 2 diabetes or aiding in its management.
• Weight loss often leads to reduced blood pressure, which decreases the risk of heart disease and stroke.
• Losing weight can improve cholesterol, reducing the risk of cardiovascular diseases.

Indirect health benefits

• Weight loss can relieve stress on joints and bones, making physical activities easier and reducing the risk of osteoarthritis and injuries.
• Many users report improved sleep quality and reduced sleep apnea symptoms.
• Weight loss can lead to better mental health outcomes, including reduced depression and anxiety.

Direct lifestyle benefits

• Losing weight makes it easier to engage in physical activities, which can further enhance weight loss and overall health.
• Users often report feeling more energetic and less fatigued.
• Many users enjoy the benefit of fitting into smaller-sized clothes and having a wider variety of clothing options.

Indirect lifestyle benefits

• Weight loss can increase confidence and encourage more social interaction, improving relationships and quality of life.
• People find they can travel more comfortably and participate in activities such as hiking, biking, or even simple walks that were challenging before.
• Increased energy and improved health can lead to better focus and productivity at work.

Many users expressed frustration with previous weight loss attempts and health issues like hypertension and pre-diabetes. They sought a solution to manage their weight effectively.

Common side effects included nausea, vomiting, diarrhea, and constipation. Users found that starting with a lower dose and gradually increasing it helped mitigate these effects. Some also recommended dietary adjustments, such as eating smaller, more frequent meals and avoiding high-fat foods, to alleviate gastrointestinal discomfort.

Many reported significant weight loss, leading to improvements in conditions like hypertension, pre-diabetes, and sleep apnea. These health benefits often resulted in reduced medication needs and enhanced overall well-being.

Users frequently noted increased self-confidence and satisfaction with their appearance as they lost weight. This boost in body image often motivated them to maintain healthier lifestyles.

The average rating from Wegovy reviews on drugs.com is 7.4/10, equivalent to 3.7* using the standard 5 star scale used by popular review platforms in the UK such as Trustpilot and Google.

There are multiple reasons why Wegovy may not be suitable for some people, including:

• people with a known allergy to semaglutide or any of the ingredients in Wegovy
• those with certain medical conditions or who are taking medications that interact negatively with Wegovy should not use it. This includes people with a history of pancreatitis, gastrointestinal disease, or thyroid cancer. Wegovy can also interact negatively with some oral contraceptives, so a barrier should also be used.
• those under 18 years of age or over 75 years old.

Wegovy is a prescription-only medication, and the decision to prescribe it rests with a healthcare provider. They will evaluate the patient’s overall health, medical history, and specific weight loss needs to determine eligibility. Take our free online assessment now. 

Depending on your individual weight loss journey, your clinician might suggest that Wegovy weight loss treatment will be most effective when taken in combination with other weight loss methods. This may include adopting a healthy diet with fewer calories and increasing physical activity. Sustainable weight loss requires a comprehensive approach that includes both medical treatment and lifestyle modifications.

Wegovy can be obtained through various channels in the UK, including Medicspot. 

The price of Wegovy in the UK from Medicspot ranges from £179 (4 x 0.25mg doses) to £259 per pen (4 x 2.4mg doses). 

The daily cost of Wegovy ranges from £6.39 per day (0.25mg dose) to £9.25 day (2.4mg dose).

Heres’s a full breakdown of the cost of Wegovy from Medicspot:

• Wegovy 0.25 mg – £129 (save £50 on your first dose)
• Wegovy 0.25 mg – £179 (if you continue on the 0.25 mg dose)
• Wegovy 0.5 mg – £189
• Wegovy 1.0 mg – £199
• Wegovy 1.7 mg – £209
• Wegovy 2.4 mg – £259

Investing in Wegovy can lead to significant health benefits, potentially reducing medical expenses related to weight-related conditions, such as heart disease and complications from poor glycemic control. Improved health can also enhance quality of life and productivity. Additionally, managing weight effectively with Wegovy can reduce the need for other medications and treatments, offering long-term savings.

Yes, Wegovy can be purchased online from licensed pharmacies. When buying online, ensure the pharmacy is reputable and registered with the General Pharmaceutical Council (GPhC) to avoid counterfeit medications. Please note that a clinical assessment and valid prescription are required in order to obtain Wegovy.

Wegovy is sometimes available on the NHS for the treatment of obesity. Patients should consult with their GP for more information about obtaining Wegovy through the NHS. It is prescribed based on specific criteria to ensure it is suitable for the patient’s condition.

With Medicspot the cost of the private prescription itself is free, and the cost of the medication is £179 for a 4 week supply of the starting dose (0.25mg).

You’re already in the right place: Medicspot runs a responsible online private weight loss clinic. To check your eligibility, take our online questionnaire.

Wegovy might not be available through the NHS except in specific medical conditions related to obesity management. Private weight loss services are also usually quicker than the NHS.

Private prescriptions for Wegovy must comply with the same regulatory standards as other medications. Healthcare providers are required to ensure the medication is suitable for the patient’s condition and that all necessary medical evaluations are performed. The prescription must be issued by a licensed medical professional.

Coverage for Wegovy under private health insurance in the UK varies by provider and policy. Some insurance plans may cover the medication if prescribed for a medical condition like obesity or type 2 diabetes. Check your policy, and contact your insurer if in doubt.

During a consultation for a private prescription of Wegovy, the healthcare provider will conduct a thorough review of your medical history, current medications, and overall health. They will record your BMI, discuss your weight loss goals, and determine if Wegovy is appropriate for you. If prescribed, they will explain the dosage, administration method (Wegovy is an injectable medication), potential side effects, and schedule follow-up appointments to monitor your progress. With Medicspot this process all takes place via a convenient online written assessment which is then reviewed by a clinician. 

Wegovy underwent extensive clinical trials to evaluate its safety and efficacy. It was tested in multiple phases involving thousands of participants. Further testing is ongoing.

In the UK Wegovy is authorised by the MHRA. Wegovy has also received official approvals from other regulatory bodies internationally such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).